Clinical Trial

Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Name: Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy — clinical trial record (NCT07637942)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CREATE

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

Phase IV, multi-site, open-label, non-randomized study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) during pregnancy and postpartum.

Trial Details

NCT Number	NCT07637942
Lead Sponsor	International Maternal Pediatric Adolescent AIDS Clinical Trials Group Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
Conditions	HIV -1 Infection
Enrollment	40 participants
Start Date	2026-07-15
Primary Completion	2028-02-15 (estimated)
Study Completion	2028-02-15 (estimated)
Updated on ClinicalTrials.gov	2026-06-10